| Disclosure of consolidated statement of financial position of discontinued operations [text block] |
| |
|
November 6,
2022
|
|
|
December 31,
2021
|
|
|
ASSETS
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
406
|
|
|
$
|
3,171
|
|
|
Trade receivables
|
|
|
1,047
|
|
|
|
8,486
|
|
|
Other accounts receivable
|
|
|
2,194
|
|
|
|
11,198
|
|
|
Loans receivable
|
|
|
1,010
|
|
|
|
2,708
|
|
|
Biological assets
|
|
|
444
|
|
|
|
1,435
|
|
|
Inventories
|
|
|
6,784
|
|
|
|
9,715
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
11,885
|
|
|
|
36,713
|
|
|
Non-current assets:
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
14,645
|
|
|
|
21,236
|
|
|
Derivative assets
|
|
|
-
|
|
|
|
14
|
|
|
Right-of-use assets, net
|
|
|
10,999
|
|
|
|
14,570
|
|
|
Intangible assets, net
|
|
|
17,157
|
|
|
|
22,846
|
|
|
Goodwill
|
|
|
-
|
|
|
|
107,854
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
42,801
|
|
|
|
166,520
|
|
| |
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
54,686
|
|
|
$
|
203,233
|
|
| |
|
November 6,
2022
|
|
|
December 31,
2021
|
|
|
LIABILITIES
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
Trade payables
|
|
$
|
7,266
|
|
|
$
|
4,667
|
|
|
Bank loans and credit facilities
|
|
|
3,774
|
|
|
|
8,684
|
|
|
Other accounts payable and accrued expenses
|
|
|
25,217
|
|
|
|
14,019
|
|
|
Current maturities of operating lease liabilities
|
|
|
869
|
|
|
|
841
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
37,126
|
|
|
|
28,211
|
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
|
|
Operating lease liabilities
|
|
|
13,517
|
|
|
|
14,883
|
|
|
Deferred tax liability, net
|
|
|
2,872
|
|
|
|
4,065
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
16,389
|
|
|
|
18,948
|
|
| |
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
53,515
|
|
|
$
|
47,159
|
|
|
| Disclosure of analysis of single amount of discontinued operations [text block] |
| |
|
Period ended November 6,
|
|
|
Year ended December 31
|
|
| |
|
2022
|
|
|
2021
|
|
| |
|
|
|
|
Revenues
|
|
$
|
28,171
|
|
|
$
|
20,247
|
|
|
Cost of revenues
|
|
|
24,227
|
|
|
|
16,960
|
|
| |
|
|
|
|
|
|
|
|
|
Gross profit before fair value adjustments
|
|
|
3,944
|
|
|
|
3,287
|
|
| |
|
|
|
|
|
|
|
|
|
Fair value adjustments:
|
|
|
|
|
|
|
|
|
|
Unrealized change in fair value of biological assets
|
|
|
399
|
|
|
|
902
|
|
|
Realized fair value adjustments on inventory sold in the period
|
|
|
(2,528
|
)
|
|
|
(226
|
)
|
| |
|
|
|
|
|
|
|
|
|
Total fair value adjustments
|
|
|
(2,129
|
)
|
|
|
676
|
|
| |
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
1,815
|
|
|
|
3,963
|
|
| |
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
38,464
|
|
|
|
14,998
|
|
|
Impairment of goodwill, intangible assets, right-of-use assets and fixed assets
|
|
|
115,112
|
|
|
|
-
|
|
|
Selling and marketing expenses
|
|
|
4,912
|
|
|
|
2,270
|
|
|
Restructuring expenses
|
|
|
4,506
|
|
|
|
-
|
|
|
Share-based compensation
|
|
|
1,130
|
|
|
|
2,049
|
|
| |
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
164,124
|
|
|
|
19,317
|
|
| |
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(162,309
|
)
|
|
|
(15,354
|
)
|
| |
|
|
|
|
|
|
|
|
|
Finance expenses, net
|
|
|
(5,264
|
)
|
|
|
(2,495
|
)
|
| |
|
|
|
|
|
|
|
|
|
Loss before income taxes
|
|
|
(167,573
|
)
|
|
|
(17,849
|
)
|
|
Income tax expense (benefit)
|
|
|
(1,194
|
)
|
|
|
5
|
|
| |
|
|
|
|
|
|
|
|
|
Net loss from discontinued operations, net of tax
|
|
$
|
(166,379
|
)
|
|
$
|
(17,854
|
)
|
|